Therapeutic focus 01
Vaccine intelligence since 2007
Bringing life to vaccine strategy.
A boutique intelligence firm sitting between vaccine candidate and market. Founded in the UK, we blend disease insight, epidemiology, and commercial intelligence to drive vaccine portfolios forward.
~20
Years of vaccine focus
14
Vaccine therapeutic areas
8.3 bn
People worth protecting
∞
Questions worth asking
01 Portfolio
Mapping almost every new vaccine opportunity.
MarketVIEW is a targeted assessment of vaccine opportunity at the pathogen or disease level, combining robust epidemiology with forward-looking commercial analysis. Each product includes a detailed Excel-based value and volume forecast model, alongside an executive-ready presentation summarising key insights and strategic implications.
Therapeutic focus 02
Travel
Therapeutic focus 03
Maternal/Pediatric
Therapeutic focus 04
Endemic/diarrheal
Therapeutic focus 05
Adolescent/STD
Therapeutic focus 06
Hospital
Therapeutic focus 07
Chronic/Addiction
Therapeutic focus 08
Hepatitis
Therapeutic focus 09
Elderly
02 News and latest analysis
Recent & forthcoming.
Respiratory |Flu/COVID-19 combination
Global seasonal influenza market + COMBOs to 2040
Sanofi versus CSL Seqirus — who's winning the race in global differentiated vaccines? What will be the impact of mRNA, now approved as a combination in the EU? Our new global analysis has the full picture.
US healthcare |commentary
New US vaccine policy - lasting impact?
US vaccine policy has broken with the past, triggering a once-in-a-generation shake-up in recommendations, governance, funding and liability that is reshaping the US vaccine market.
Vaccine R&D pipeline |analysis
Vaccines/mRNA/RNA Tech Strategic Pipeline Review
Analysis of the current and historical vaccine research and development (R&D) pipeline is a critical component of any organisation's competitive intelligence effort. Our database will be refreshed during Q2 2026.
03 Capability/Approach
Built around portfolio decisions, not slide formats.
Asset diligence
Mechanism, target product profile, comparator landscape, and probability-of-success framing for licensing or in-house pipeline decisions.
Indication mapping
Where adjacent vaccines, off-label use, and emerging epidemiology widen — or close — a commercial window.
Forecast review
Independent stress-test of internal forecasts: assumptions, sensitivity, payer behaviour, real-world uptake calibration.
Policy tracking
Continuous read of ACIP, JCVI, STIKO, HAS, NITAG signal — interpreted not just summarised.
Adult immunisation
Pneumococcal, RSV, zoster, influenza, COVID combinations — where adult uptake is being made or lost.
Maternal & paediatric
Schedule integration, programmatic constraints, equity dynamics across high- and low-income geographies.
Tender & access
UNICEF, PAHO, Gavi, EU joint procurement and national tender behaviour — and what it means for net price.
Travel vaccines
Expert insights on global travel immunization strategy, risk, and market analytics.
04 About
A vaccine intelligence identity, refreshed.
I believe vaccines are one of humanity's greatest achievements. Few innovations have saved as many lives, across every age group and every part of the world. That belief is what led me to found VacZine Analytics in 2007, to help our clients build the evidence, confidence, and momentum needed to bring the next generation of vaccines forward.
VacZine Analytics has been working alongside the vaccine industry since 2007 — long enough to remember when adult immunisation was a slide-deck afterthought, and long enough to know which questions are actually load-bearing. We are deliberately boutique: tight teams, deep files, no junior layer in front of the analyst.
05 Contact
Request a briefing or report sample.
A short three-step request. We respond within two working days from a UK address. Lawful basis: consent (GDPR Art. 6(1)(a)).
06 FAQ
Common questions, briefly answered.
What does working with VacZine Analytics actually look like?
Usually one of two shapes: a syndicated report (single copy access) or a bespoke project with a defined deliverable and timeline. Both start with a 30-minute call so we can scope properly. All engagements run under our .
Do you publish public reports?
Selectively, but mainly through shorter white papers or expert pieces. Our syndicated catalogue reports which cover our focus therapeutic areas are licensable on a non-exclusive, non-transferable basis. Most other work is single-client and confidential. Ask for the catalogue and we'll send what's currently live.
How does VacZine Analytics report licensing work?
We license our syndicated reports on a non-exclusive, non-transferable basis. This is standard practice across market intelligence and data providers, and it means clients have broad rights to use the content internally for their own business purposes, but do not acquire ownership of the underlying intellectual property or the right to redistribute it. “Non-exclusive” allows us to license the same report to multiple organisations, keeping prices at a sustainable level, while “non-transferable” ensures that only the contracting client (and its authorised personnel) may access the materials, not external agencies, partners, or other third parties.
How is your work different from a big-three consultancy?
We're deliberately small and vaccine-only. There's no junior layer in front of the analyst, no rotating staffing, and no sector-tourist framing. We've been doing this since 2007 — the institutional memory is the product.
What about data and confidentiality?
Standard mutual NDA before any client material is shared. Our data infrastructure runs on UK-hosted services with role-based access. See the for what we collect on this site itself.
How do you handle policy / regulatory references?
Public-domain meetings, slide decks, and policy minutes — ACIP, JCVI, STIKO, HAS, EMA, FDA, WHO SAGE, MHRA — are read in primary form, not via news summaries. Trial registry IDs are checked against ClinicalTrials.gov and EU CTR. Sponsorship trademarks are used for identification only — see the credits line at the foot of the page.